Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
VANCOUVER, B.C. and DOYLESTOWN, Pa., March 23, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company has appointed Daniel Burgess to the Board of Directors and Audit Committee effective immediately.
Mr. Burgess has more than 25 years of executive level operating experience in biotech companies, including substantial experience in the anti-infective field. He is currently a Venture Partner at SV Life Sciences, is Chairman of the Board of Nabriva Therapeutics (NASDAQ:NBRV) and is on the board of Cidara Therapeutics (NASDAQ:CDTX) as well as several private biotechnology companies. In addition, he is Chairman of Biocom, the life science industry organization of California that represents more than 800 member companies. Prior to his current roles, Mr. Burgess was President of Rempex Pharmaceuticals, a company he co-founded in 2011 and subsequently sold to The Medicines Company in December 2013. Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. (now Allergan) in 2011. Previously, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc. Prior to Hollis-Eden, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Doylestown, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858.717.2310 Email: [email protected]
